Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 1638 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
This article has been cited by
1Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy—an emerging problem and solutions offered by diabetes technology
A. Pfützner,D. Klonoff,L. Heinemann,N. Ejskjaer,J. Pickup
Endocrine.2017;56(1)212
[DOI]
2Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus
Hala Ahmadieh,Sami Azar
Diabetes Technology & Therapeutics.2017;19(9)507
[DOI]
3Neuromodulatory effects of anti-diabetes medications: A mechanistic review
Habib Yaribeygi,Milad Ashrafizadeh,Neil C. Henney,Thozhukat Sathyapalan,Tannaz Jamialahmadi,Amirhossein Sahebkar
Pharmacological Research.2020;152(9)104611
[DOI]
4Sulfonylurea Glimepiride: A Proven Cost Effective, Safe and Reliable War Horse in Combating Hyperglycemia in Type 2 Diabetes
Udaya M. Kabadi
Journal of Diabetes Mellitus.2015;05(04)211
[DOI]
5Complicaciones agudas hiperglucémicas e hipoglucémicas
I. Capel,I. Berges-Raso
Medicine - Programa de Formación Médica Continuada Acreditado.2016;12(18)1035
[DOI]
6SGLT2 Inhibitors: Far Too Many Cautions and Alerts and Limited Efficacy
Udaya M Kabadi
Journal of Diabetes, Metabolic Disorders & Control.2016;3(5)1035
[DOI]
7Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Abd A. Tahrani,Anthony H. Barnett,Clifford J. Bailey
Nature Reviews Endocrinology.2016;12(10)566
[DOI]
8Les pièges de l’acidocétose diabétique
S. Ayed,A. Bouguerba,P. Ahmed,J. Barchazs,M. Boukari,D. Goldgran-Toledano,C. Bornstain,F. Vincent
Réanimation.2015;24(6)668
[DOI]
9Acid-base and electrolyte disorders associated with the use of antidiabetic drugs
Theodosios Filippatos,Eleftheria Tzavella,Christos Rizos,Moses Elisaf,George Liamis
Expert Opinion on Drug Safety.2017;16(10)1121
[DOI]
10Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies
Vasilios Tsimihodimos,Theodosios D. Filippatos,Moses S. Elisaf
Expert Opinion on Drug Metabolism & Toxicology.2017;13(4)399
[DOI]
11Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials
Rizwana Parveen,Nidhi Bharal Agarwal,Neelam Kaushal,Ghanshyam Mali,Sheikh Raisuddin
Expert Opinion on Pharmacotherapy.2016;17(1)105
[DOI]
12Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes
Kalliopi Pafili,Efstratios Maltezos,Nikolaos Papanas
Expert Opinion on Drug Metabolism & Toxicology.2016;12(11)1367
[DOI]
13The Effect and Safety of Dapagliflozin in Patients with Type 2 Diabetes: A Single-Institution Pharmacovigilance Review
Hyung Woo Lee,Sun Joon Moon,Hee Sim Han,Eun Jeong Shin,Jin Hee Baek,Hyun-Joo Han,Young Min Cho,Kwi Suk Kim
The Journal of Korean Diabetes.2017;18(4)275
[DOI]
  Feedback 
  Subscribe 

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal